OBJECTIVE : It has been confirmed that the dysregulation of long noncoding RNAs (lncRNAs) is associated with various diseases, especially cancer. LncRNA MAGI2 antisense RNA 3 (MAGI2-AS3) has been reported to be involved in the progression of bladder cancer and breast cancer. In this study, we aimed to explore its expression and clinical significance in glioma. METHODS : Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assays were performed to detect the expression levels of MAGI2-AS3 in fresh glioma and matched adjacent normal brain tissue specimens, which were collected from 178 patients. Then the association between MAGI2-AS3 expression and clinical-pathological parameters were further evaluated using the Chi-square test. The overall survival (OS) was analyzed by the log-rank test, and the survival curves were plotted according to Kaplan-Meier. Univariate and multivariate analyses were performed to analyze the prognostic significance of MAGI2-AS3 expression. RESULTS : We found that the relative expression level of MAGI2-AS3 in glioma tissues was significantly lower than those in adjacent normal brain tissues (p<0.01). Lower MAGI2-AS3 expression was observed to be positively correlated with the World Health Organization (WHO) grade (p=0.031) and KPS score (p=0.003) in glioma patients. The Kaplan-Meier analysis indicated that patients with low MAGI2-AS3 expression levels tended to have worse overall survival than those with high levels of MAGI2-AS3 expression (p=0.0042). In the multivariate analysis, we further observed that MAGI2-AS3 expression in glioma tissues was an independent prognostic factor for overall survival (HR=3.098, 95% CI: 1.289-4.118, p=0.014). CONCLUSIONS : MAGI2-AS3 expression represents a significant favorable prognostic factor for patients with glioma.